Kinetic and inhibition studies on human Jumonji-C (JmjC) domain-containing protein 5
Jumonji-C (JmjC) domain-containing protein 5 (JMJD5) is a human 2-oxoglutarate (2OG) and Fe(<sub>II</sub>)-dependent oxygenase which catalyses the post-translational C3 hydroxylation of arginyl-residues and which is linked to the circadian rhythm and to cancer biology through as yet unid...
| Główni autorzy: | , , , , |
|---|---|
| Format: | Journal article |
| Język: | English |
| Wydane: |
Royal Society of Chemistry
2023
|
| _version_ | 1826310313293643776 |
|---|---|
| author | Tumber, A Saleh, E Brewitz, L Corner, TP Schofield, CJ |
| author_facet | Tumber, A Saleh, E Brewitz, L Corner, TP Schofield, CJ |
| author_sort | Tumber, A |
| collection | OXFORD |
| description | Jumonji-C (JmjC) domain-containing protein 5 (JMJD5) is a human 2-oxoglutarate (2OG) and Fe(<sub>II</sub>)-dependent oxygenase which catalyses the post-translational C3 hydroxylation of arginyl-residues and which is linked to the circadian rhythm and to cancer biology through as yet unidentified mechanisms. We report robust solid phase extraction coupled to mass spectrometry (SPE-MS)-based JMJD5 assays which enable kinetic and high-throughput inhibition studies. The kinetic studies reveal that some synthetic 2OG derivatives, notably including a 2OG derivative with a cyclic carbon backbone (<i>i.e.</i> (1<i>R</i>)-3-(carboxycarbonyl)cyclopentane-1-carboxylic acid), are efficient alternative cosubstrates of JMJD5 and of factor inhibiting hypoxia-inducible transcription factor HIF-α (FIH), but not of the Jumonji-C (JmjC) histone <i>N</i><sup>ε</sup>-methyl lysine demethylase KDM4E, apparently reflecting the closer structural similarity of JMJD5 and FIH. The JMJD5 inhibition assays were validated by investigating the effect of reported 2OG oxygenase inhibitors on JMJD5 catalysis; the results reveal that broad-spectrum 2OG oxygenase inhibitors are also efficient JMJD5 inhibitors (<i>e.g. N</i>-oxalylglycine, pyridine-2,4-dicarboxylic acid, ebselen) whereas most 2OG oxygenase inhibitors that are in clinical use (<i>e.g.</i> roxadustat) do not inhibit JMJD5. The SPE-MS assays will help enable the development of efficient and selective JMJD5 inhibitors for investigating the biochemical functions of JMJD5 in cellular studies. |
| first_indexed | 2024-03-07T07:50:06Z |
| format | Journal article |
| id | oxford-uuid:868b8d2e-6ba9-4170-a1a8-80d4d3a0d9d8 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:50:06Z |
| publishDate | 2023 |
| publisher | Royal Society of Chemistry |
| record_format | dspace |
| spelling | oxford-uuid:868b8d2e-6ba9-4170-a1a8-80d4d3a0d9d82023-07-10T15:34:09ZKinetic and inhibition studies on human Jumonji-C (JmjC) domain-containing protein 5Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:868b8d2e-6ba9-4170-a1a8-80d4d3a0d9d8EnglishSymplectic ElementsRoyal Society of Chemistry2023Tumber, ASaleh, EBrewitz, LCorner, TPSchofield, CJJumonji-C (JmjC) domain-containing protein 5 (JMJD5) is a human 2-oxoglutarate (2OG) and Fe(<sub>II</sub>)-dependent oxygenase which catalyses the post-translational C3 hydroxylation of arginyl-residues and which is linked to the circadian rhythm and to cancer biology through as yet unidentified mechanisms. We report robust solid phase extraction coupled to mass spectrometry (SPE-MS)-based JMJD5 assays which enable kinetic and high-throughput inhibition studies. The kinetic studies reveal that some synthetic 2OG derivatives, notably including a 2OG derivative with a cyclic carbon backbone (<i>i.e.</i> (1<i>R</i>)-3-(carboxycarbonyl)cyclopentane-1-carboxylic acid), are efficient alternative cosubstrates of JMJD5 and of factor inhibiting hypoxia-inducible transcription factor HIF-α (FIH), but not of the Jumonji-C (JmjC) histone <i>N</i><sup>ε</sup>-methyl lysine demethylase KDM4E, apparently reflecting the closer structural similarity of JMJD5 and FIH. The JMJD5 inhibition assays were validated by investigating the effect of reported 2OG oxygenase inhibitors on JMJD5 catalysis; the results reveal that broad-spectrum 2OG oxygenase inhibitors are also efficient JMJD5 inhibitors (<i>e.g. N</i>-oxalylglycine, pyridine-2,4-dicarboxylic acid, ebselen) whereas most 2OG oxygenase inhibitors that are in clinical use (<i>e.g.</i> roxadustat) do not inhibit JMJD5. The SPE-MS assays will help enable the development of efficient and selective JMJD5 inhibitors for investigating the biochemical functions of JMJD5 in cellular studies. |
| spellingShingle | Tumber, A Saleh, E Brewitz, L Corner, TP Schofield, CJ Kinetic and inhibition studies on human Jumonji-C (JmjC) domain-containing protein 5 |
| title | Kinetic and inhibition studies on human Jumonji-C (JmjC) domain-containing protein 5 |
| title_full | Kinetic and inhibition studies on human Jumonji-C (JmjC) domain-containing protein 5 |
| title_fullStr | Kinetic and inhibition studies on human Jumonji-C (JmjC) domain-containing protein 5 |
| title_full_unstemmed | Kinetic and inhibition studies on human Jumonji-C (JmjC) domain-containing protein 5 |
| title_short | Kinetic and inhibition studies on human Jumonji-C (JmjC) domain-containing protein 5 |
| title_sort | kinetic and inhibition studies on human jumonji c jmjc domain containing protein 5 |
| work_keys_str_mv | AT tumbera kineticandinhibitionstudiesonhumanjumonjicjmjcdomaincontainingprotein5 AT salehe kineticandinhibitionstudiesonhumanjumonjicjmjcdomaincontainingprotein5 AT brewitzl kineticandinhibitionstudiesonhumanjumonjicjmjcdomaincontainingprotein5 AT cornertp kineticandinhibitionstudiesonhumanjumonjicjmjcdomaincontainingprotein5 AT schofieldcj kineticandinhibitionstudiesonhumanjumonjicjmjcdomaincontainingprotein5 |